ARWR
Arrowhead Pharmaceuticals, Inc.
Price Chart
Latest Quote
$81.82
+0.78 (+0.96%)
Current Price
| Previous Close | $81.04 |
| Open | $82.98 |
| Day High | $84.55 |
| Day Low | $79.80 |
| Volume | 3,307,507 |
Stock Information
| Shares Outstanding | 140.86M |
| Total Debt | $1.38B |
| Cash Equivalents | $1.78B |
| Revenue | $622.01M |
| Net Income | $-300.91M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $11.52B |
| EPS (TTM) | $-2.27 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $10.37B |
| Sales | $622.01M |
| Income | $-300.91M |
| Book/sh | $4.37 |
| Cash/sh | $12.65 |
| Employees | 711 |
Financial Ratios
| Quick Ratio | 6.09 |
| Current Ratio | 6.23 |
| Debt/Eq | 231.05 |
Returns & Margins
| ROA | -7.22% |
| ROE | -42.37% |
| Gross Margin | 100.00% |
| Operating Margin | -191.57% |
| Profit Margin | -48.38% |
Ownership
| Insider Ownership | 3.67% |
| Institutional Ownership | 88.56% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -18.85 |
| P/S | 18.53 |
| P/B | 18.73 |
Analyst Data
| Recommendation | buy |
| Target Price | $89.08 |
Technical Indicators
| SMA20 | $75.77 |
| SMA50 | $74.14 |
| SMA200 | $58.12 |
| RSI | 56.58 |
| ATR | 4.2674 |
| Shares Float | 122.78M |
| Short Float | 12.25% |
| Short Ratio | 7.50 |
| Volatility | 1.27 |
| Rel Volume | 2.40 |
Performance History
| Week | +9.96% |
| Month | +11.81% |
| Quarter | +43.64% |
| 6 Months | +26.54% |
| YTD | +20.70% |
| Year | +427.87% |
| 3 Years | +132.11% |
| 5 Years | -7.77% |
| 10 Years | +1291.50% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $81.82 | 3,863,400 |
| 2026-06-17 | $81.04 | 3,100,000 |
| 2026-06-16 | $76.55 | 917,100 |
| 2026-06-15 | $77.15 | 1,115,700 |
| 2026-06-12 | $74.52 | 1,182,200 |
| 2026-06-11 | $74.41 | 1,348,700 |
| 2026-06-10 | $70.73 | 1,546,400 |
| 2026-06-09 | $73.33 | 1,415,100 |
| 2026-06-08 | $73.86 | 1,204,700 |
| 2026-06-05 | $73.09 | 1,227,800 |
| 2026-06-04 | $75.16 | 1,130,300 |
| 2026-06-03 | $72.55 | 1,484,600 |
| 2026-06-02 | $70.82 | 2,009,700 |
| 2026-06-01 | $75.20 | 2,287,800 |
| 2026-05-29 | $77.91 | 1,441,900 |
| 2026-05-28 | $79.05 | 1,016,700 |
| 2026-05-27 | $78.99 | 1,288,300 |
| 2026-05-26 | $78.68 | 1,623,500 |
| 2026-05-22 | $74.95 | 1,401,600 |
| 2026-05-21 | $75.54 | 1,580,100 |
| 2026-05-20 | $77.14 | 1,582,600 |
| 2026-05-19 | $73.18 | 2,120,900 |
About Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.
đ° Latest News
Arrowhead Pharmaceuticals Lines Up SHASTA Readout as REDEMPLO Launch Gains Traction
MarketBeat âĸ 2026-06-05T18:03:29Z
Arrowhead Data On Plozasiran Expands Cardiometabolic Opportunity And Investor Focus
Simply Wall St. âĸ 2026-05-26T19:16:02Z
Bernstein Lifts PT on Arrowhead Pharmaceuticals (ARWR) Following Biotechâs Solid Start to 2026
Insider Monkey âĸ 2026-05-26T12:43:39Z
Arrowhead Pharmaceuticals Eyes Q3 SHASTA Data as REDEMPLO Approvals Build Momentum
MarketBeat âĸ 2026-05-20T14:07:58Z
Arrowhead Pharmaceuticals Eyes $4B REDEMPLO Opportunity as RNAi Pipeline Readouts Near
MarketBeat âĸ 2026-05-14T09:09:24Z
Assessing Arrowhead Pharmaceuticals (ARWR) Valuation After Its Recent Share Price Momentum
Simply Wall St. âĸ 2026-05-12T23:18:51Z
Arrowhead (ARWR) Q2 2026 Earnings Transcript
Motley Fool âĸ 2026-05-08T14:17:55Z
Arrowhead Pharmaceuticals Q2 Earnings Call Highlights
MarketBeat âĸ 2026-05-07T22:39:04Z
Arrowhead and Madrigal sign global licence for MASH RNAi therapy
Pharmaceutical Technology âĸ 2026-05-06T10:29:05Z
Should Madrigalâs ARO-PNPLA3 License Deal Reshape the MASH Strategy for Madrigal Pharmaceuticals (MDGL) Investors?
Simply Wall St. âĸ 2026-05-06T03:15:59Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $829,448,000 | $3,551,000 | $240,735,000 | $243,231,000 |
| Operating Revenue | $829,448,000 | $3,551,000 | $240,735,000 | $243,231,000 |
| Expenses | ||||
| Interest Expense | $89,361,000 | $32,352,000 | $18,326,000 | $0 |
| Total Expenses | $731,102,000 | $604,631,000 | $445,737,000 | $421,738,000 |
| Other Income Expense | $5,259,000 | $-1,748,000 | $1,538,000 | $765,000 |
| Other Non Operating Income Expenses | $5,259,000 | $-1,748,000 | $1,538,000 | $765,000 |
| Net Non Operating Interest Income Expense | $-52,072,000 | $-9,632,000 | $-3,027,000 | $5,033,000 |
| Interest Expense Non Operating | $89,361,000 | $32,352,000 | $18,326,000 | $0 |
| Operating Expense | $731,102,000 | $604,631,000 | $445,737,000 | $421,738,000 |
| General And Administrative Expense | $121,915,000 | $96,820,000 | $90,932,000 | $124,431,000 |
| Total Other Finance Cost | - | - | - | $-5,033,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-1,631,000 | $-599,493,000 | $-205,275,000 | $-176,063,000 |
| Net Interest Income | $-52,072,000 | $-9,632,000 | $-3,027,000 | $5,033,000 |
| Interest Income | $37,289,000 | $22,720,000 | $15,299,000 | $5,033,000 |
| Normalized Income | $-1,631,000 | $-599,493,000 | $-205,275,000 | $-176,063,000 |
| Net Income From Continuing And Discontinued Operation | $-1,631,000 | $-599,493,000 | $-205,275,000 | $-176,063,000 |
| Total Operating Income As Reported | $98,346,000 | $-601,080,000 | $-205,002,000 | $-178,507,000 |
| Net Income Common Stockholders | $-1,631,000 | $-599,493,000 | $-205,275,000 | $-176,063,000 |
| Net Income | $-1,631,000 | $-599,493,000 | $-205,275,000 | $-176,063,000 |
| Net Income Including Noncontrolling Interests | $30,114,000 | $-609,693,000 | $-209,275,000 | $-176,494,000 |
| Net Income Continuous Operations | $30,114,000 | $-609,693,000 | $-209,275,000 | $-176,494,000 |
| Pretax Income | $51,533,000 | $-612,460,000 | $-206,491,000 | $-172,709,000 |
| Interest Income Non Operating | $37,289,000 | $22,720,000 | $15,299,000 | $5,033,000 |
| Operating Income | $98,346,000 | $-601,080,000 | $-205,002,000 | $-178,507,000 |
| Depreciation Amortization Depletion Income Statement | $2,028,000 | $1,941,000 | $1,617,000 | $1,614,000 |
| Depreciation And Amortization In Income Statement | $2,028,000 | $1,941,000 | $1,617,000 | $1,614,000 |
| Per Share | ||||
| Diluted EPS | $-0.01 | $-5.00 | $-1.92 | $-1.67 |
| Basic EPS | $-0.01 | $-5.00 | $-1.91 | $-1.63 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $164,822,000 | $-561,513,000 | $-175,672,000 | $-162,288,000 |
| Reconciled Depreciation | $23,928,000 | $18,595,000 | $12,493,000 | $10,421,000 |
| EBITDA (Bullshit earnings) | $164,822,000 | $-561,513,000 | $-175,672,000 | $-162,288,000 |
| EBIT | $140,894,000 | $-580,108,000 | $-188,165,000 | $-172,709,000 |
| Diluted Average Shares | $133,758,000 | $119,784,000 | $107,312,000 | $105,960,000 |
| Basic Average Shares | $133,758,000 | $119,784,000 | $107,312,000 | $105,960,000 |
| Diluted NI Availto Com Stockholders | $-1,631,000 | $-599,493,000 | $-205,275,000 | $-176,063,000 |
| Minority Interests | $-31,745,000 | $10,200,000 | $4,000,000 | $431,000 |
| Tax Provision | $21,419,000 | $-2,767,000 | $2,784,000 | $3,785,000 |
| Research And Development | $607,159,000 | $505,870,000 | $353,188,000 | $297,307,000 |
| Selling General And Administration | $121,915,000 | $96,820,000 | $90,932,000 | $124,431,000 |
| Other Gand A | $59,214,000 | $28,849,000 | $24,135,000 | $124,431,000 |
| Salaries And Wages | $62,701,000 | $67,971,000 | $66,797,000 | $105,167,000 |
Fetched: 2026-06-18
Balance Sheet (Annual)
| Metric | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $459,191,000 | $176,882,000 | $261,081,000 | $386,558,000 |
| Total Assets | $1,385,295,000 | $1,139,802,000 | $765,552,000 | $691,939,000 |
| Total Non Current Assets | $434,656,000 | $444,331,000 | $349,080,000 | $286,640,000 |
| Other Non Current Assets | $1,389,000 | $4,482,000 | $3,259,000 | $218,000 |
| Goodwill And Other Intangible Assets | $6,861,000 | $8,562,000 | $10,262,000 | $11,962,000 |
| Other Intangible Assets | $6,861,000 | $8,562,000 | $10,262,000 | $11,962,000 |
| Current Assets | $950,639,000 | $695,471,000 | $416,472,000 | $405,299,000 |
| Other Current Assets | $13,516,000 | $4,973,000 | $4,033,000 | $20,204,000 |
| Prepaid Assets | $10,933,000 | $9,537,000 | $8,813,000 | $7,289,000 |
| Receivables | $6,824,000 | $0 | $0 | $1,410,000 |
| Accounts Receivable | $6,824,000 | $0 | $0 | $1,410,000 |
| Cash Cash Equivalents And Short Term Investments | $919,366,000 | $680,961,000 | $403,626,000 | $376,396,000 |
| Cash And Cash Equivalents | $88,706,000 | $76,208,000 | $110,891,000 | $108,005,000 |
| Investmentin Financial Assets | - | - | $0 | $105,872,000 |
| Debt | ||||
| Net Debt | $166,177,000 | $316,975,000 | - | - |
| Total Debt | $366,284,000 | $510,552,000 | $115,171,000 | $81,576,000 |
| Long Term Debt And Capital Lease Obligation | $318,995,000 | $504,210,000 | $104,608,000 | $78,800,000 |
| Long Term Debt | $214,883,000 | $393,183,000 | - | - |
| Current Debt And Capital Lease Obligation | $47,289,000 | $6,342,000 | $10,563,000 | $2,776,000 |
| Current Debt | $40,000,000 | - | - | - |
| Other Current Borrowings | $40,000,000 | - | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $881,879,000 | $948,739,000 | $478,390,000 | $273,600,000 |
| Total Non Current Liabilities Net Minority Interest | $686,392,000 | $845,571,000 | $372,934,000 | $134,750,000 |
| Liabilities Heldfor Sale Non Current | $367,397,000 | $341,361,000 | $268,326,000 | $0 |
| Current Liabilities | $195,487,000 | $103,168,000 | $105,456,000 | $138,850,000 |
| Other Current Liabilities | $10,811,000 | $432,000 | $435,000 | - |
| Current Deferred Liabilities | $2,399,000 | $0 | $866,000 | $74,099,000 |
| Payables And Accrued Expenses | $134,988,000 | $96,394,000 | $93,592,000 | $61,975,000 |
| Payables | $17,674,000 | $11,388,000 | $35,866,000 | $2,868,000 |
| Accounts Payable | $17,674,000 | $11,388,000 | $35,866,000 | $2,868,000 |
| Non Current Deferred Liabilities | - | - | $0 | $55,950,000 |
| Equity | ||||
| Common Stock Equity | $466,052,000 | $185,444,000 | $271,343,000 | $398,520,000 |
| Total Equity Gross Minority Interest | $503,416,000 | $191,063,000 | $287,162,000 | $418,339,000 |
| Stockholders Equity | $466,052,000 | $185,444,000 | $271,343,000 | $398,520,000 |
| Gains Losses Not Affecting Retained Earnings | $6,443,000 | $4,750,000 | $-3,222,000 | $-136,000 |
| Other Equity Adjustments | $6,443,000 | $4,750,000 | $-3,222,000 | $-136,000 |
| Retained Earnings | $-1,627,154,000 | $-1,625,523,000 | $-1,026,030,000 | $-820,755,000 |
| Other | ||||
| Treasury Shares Number | $2,660,989 | - | - | - |
| Ordinary Shares Number | $135,701,794 | $124,376,000 | $107,312,000 | $105,960,000 |
| Share Issued | $138,362,783 | $124,376,000 | $107,312,000 | $105,960,000 |
| Tangible Book Value | $459,191,000 | $176,882,000 | $261,081,000 | $386,558,000 |
| Invested Capital | $720,935,000 | $578,627,000 | $271,343,000 | $398,520,000 |
| Working Capital | $755,152,000 | $592,303,000 | $311,016,000 | $266,449,000 |
| Capital Lease Obligations | $111,401,000 | $117,369,000 | $115,171,000 | $81,576,000 |
| Total Capitalization | $680,935,000 | $578,627,000 | $271,343,000 | $398,520,000 |
| Minority Interest | $37,364,000 | $5,619,000 | $15,819,000 | $19,819,000 |
| Treasury Stock | $53,193,000 | $0 | - | - |
| Additional Paid In Capital | $2,139,725,000 | $1,806,000,000 | $1,300,395,000 | $1,219,213,000 |
| Capital Stock | $231,000 | $217,000 | $200,000 | $198,000 |
| Common Stock | $231,000 | $217,000 | $200,000 | $198,000 |
| Long Term Capital Lease Obligation | $104,112,000 | $111,027,000 | $104,608,000 | $78,800,000 |
| Current Deferred Revenue | $2,399,000 | $0 | $866,000 | $74,099,000 |
| Current Capital Lease Obligation | $7,289,000 | $6,342,000 | $10,563,000 | $2,776,000 |
| Current Accrued Expenses | $117,314,000 | $85,006,000 | $57,726,000 | $59,107,000 |
| Net PPE | $426,406,000 | $431,287,000 | $335,559,000 | $168,588,000 |
| Accumulated Depreciation | $-80,169,000 | $-58,021,000 | $-41,951,000 | $-31,554,000 |
| Gross PPE | $506,575,000 | $489,308,000 | $377,510,000 | $200,142,000 |
| Leases | $104,425,000 | $104,410,000 | $103,813,000 | $42,017,000 |
| Construction In Progress | $15,942,000 | $188,731,000 | $166,655,000 | $56,373,000 |
| Other Properties | $125,237,000 | $110,608,000 | $101,806,000 | $96,574,000 |
| Machinery Furniture Equipment | $6,658,000 | $6,575,000 | $2,240,000 | $2,182,000 |
| Buildings And Improvements | $251,317,000 | $75,988,000 | $0 | - |
| Land And Improvements | $2,996,000 | $2,996,000 | $2,996,000 | $2,996,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $830,660,000 | $604,753,000 | $292,735,000 | $268,391,000 |
| Non Current Deferred Revenue | - | - | $0 | $55,950,000 |
| Investments And Advances | - | - | $0 | $105,872,000 |
| Held To Maturity Securities | - | - | $0 | $105,872,000 |
Fetched: 2026-06-18
Cash Flow Statement (Annual)
| Metric | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $156,886,000 | $-604,320,000 | $-330,627,000 | $-188,908,000 |
| Operating Activities | ||||
| Operating Cash Flow | $179,552,000 | $-462,851,000 | $-153,890,000 | $-136,131,000 |
| Cash Flow From Continuing Operating Activities | $179,552,000 | $-462,851,000 | $-153,890,000 | $-136,131,000 |
| Operating Gains Losses | $-3,193,000 | $80,000 | - | $4,432,000 |
| Investing Activities | ||||
| Capital Expenditure | $-22,666,000 | $-141,469,000 | $-176,737,000 | $-52,777,000 |
| Investing Cash Flow | $-129,294,000 | $-420,072,000 | $-96,155,000 | $-5,417,000 |
| Cash Flow From Continuing Investing Activities | $-129,294,000 | $-420,072,000 | $-96,155,000 | $-5,417,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $241,388,000 | $429,265,000 | $0 | $0 |
| Financing Cash Flow | $74,006,000 | $870,520,000 | $253,053,000 | $65,186,000 |
| Cash Flow From Continuing Financing Activities | $74,006,000 | $870,520,000 | $253,053,000 | $65,186,000 |
| Net Other Financing Charges | $-5,000,000 | $46,866,000 | $250,000,000 | $60,000,000 |
| Net Common Stock Issuance | $241,388,000 | $429,265,000 | $0 | $0 |
| Common Stock Issuance | $241,388,000 | $429,265,000 | $0 | $0 |
| Other | ||||
| Repayment Of Debt | $-201,625,000 | $0 | $0 | - |
| Issuance Of Debt | $10,260,000 | $392,000,000 | $0 | $0 |
| Interest Paid Supplemental Data | $19,000 | $0 | $0 | $0 |
| End Cash Position | $226,548,000 | $102,685,000 | $110,891,000 | $108,005,000 |
| Beginning Cash Position | $102,685,000 | $110,891,000 | $108,005,000 | $184,434,000 |
| Effect Of Exchange Rate Changes | $-401,000 | $4,197,000 | $-122,000 | $-67,000 |
| Changes In Cash | $124,264,000 | $-12,403,000 | $3,008,000 | $-76,362,000 |
| Proceeds From Stock Option Exercised | $28,983,000 | $2,389,000 | $3,053,000 | $5,186,000 |
| Net Issuance Payments Of Debt | $-191,365,000 | $392,000,000 | $0 | $0 |
| Net Short Term Debt Issuance | $10,260,000 | $0 | $0 | - |
| Short Term Debt Issuance | $10,260,000 | $0 | $0 | - |
| Net Long Term Debt Issuance | $-201,625,000 | $392,000,000 | $0 | $0 |
| Long Term Debt Payments | $-201,625,000 | $0 | $0 | - |
| Long Term Debt Issuance | $0 | $392,000,000 | $0 | $0 |
| Net Investment Purchase And Sale | $-106,628,000 | $-278,603,000 | $80,582,000 | $47,360,000 |
| Sale Of Investment | $689,630,000 | $442,344,000 | $326,723,000 | $270,751,000 |
| Purchase Of Investment | $-796,258,000 | $-720,947,000 | $-246,141,000 | $-223,391,000 |
| Net PPE Purchase And Sale | $-22,666,000 | $-141,469,000 | $-176,737,000 | $-52,777,000 |
| Purchase Of PPE | $-22,666,000 | $-141,469,000 | $-176,737,000 | $-52,777,000 |
| Change In Working Capital | $-18,235,000 | $25,091,000 | $-51,547,000 | $-98,293,000 |
| Change In Other Working Capital | $5,493,000 | $-2,066,000 | $-129,183,000 | $-99,008,000 |
| Change In Other Current Liabilities | $-4,605,000 | $2,240,000 | $46,590,000 | - |
| Change In Payables And Accrued Expense | $47,783,000 | $26,581,000 | $18,033,000 | $11,161,000 |
| Change In Accrued Expense | $41,497,000 | $32,117,000 | $-14,965,000 | $17,750,000 |
| Change In Payable | $6,286,000 | $-5,536,000 | $32,998,000 | $-6,589,000 |
| Change In Account Payable | $6,286,000 | $-5,536,000 | $32,998,000 | $-6,589,000 |
| Change In Prepaid Assets | $-9,939,000 | $-1,664,000 | $11,603,000 | $-19,291,000 |
| Change In Receivables | $-56,967,000 | $0 | $1,410,000 | $8,845,000 |
| Changes In Account Receivables | $-56,967,000 | $0 | $1,410,000 | $8,845,000 |
| Other Non Cash Items | $89,361,000 | $32,352,000 | $18,326,000 | $2,910,000 |
| Stock Based Compensation | $63,366,000 | $73,968,000 | $78,130,000 | $120,893,000 |
| Amortization Of Securities | $-5,789,000 | $-3,244,000 | $-2,017,000 | $2,910,000 |
| Depreciation Amortization Depletion | $23,928,000 | $18,595,000 | $12,493,000 | $10,421,000 |
| Depreciation And Amortization | $23,928,000 | $18,595,000 | $12,493,000 | $10,421,000 |
| Gain Loss On Investment Securities | $-3,193,000 | $80,000 | - | $4,432,000 |
| Net Income From Continuing Operations | $30,114,000 | $-609,693,000 | $-209,275,000 | $-176,494,000 |
| Income Tax Paid Supplemental Data | - | $3,744,000 | $0 | $2,000 |
Fetched: 2026-06-18